NASDAQ OMX

Informa's Annual Clinical and Research Excellence Awards Return for Third Year

Dela

BOSTON, June 26, 2017 (GLOBE NEWSWIRE) -- Informa's Pharma Intelligence has today announced that the third annual Clinical and Research Excellence (CARE) Awards are now open for nominations.

Pharma Intelligence - the world's leading provider of clinical and research intelligence and analysis, and home of leading brands such as Scrip, Pink Sheet and Biomedtracker - will host the awards which recognize and celebrate outstanding achievements and stand-out performers in the global R&D space.

Nominations for the CARE Awards are free and all submissions should be made via the online entry form available at www.clinicalresearchexcellence.com by December 23. All entries will be assessed by a panel of distinguished industry experts and the winners will be announced at the CARE Awards ceremony on April 25, 2018 at the Boston Harbor Hotel.

"The success of last year's CARE Awards was testament to the original mission of the CARE Awards: to recognize the extraordinary achievements of the dedicated professionals working in biopharmaceutical clinical research. The event really brings the industry together to celebrate the individuals and companies that continuously strive for excellence in everything they do and are making a real difference to lives across the world," says Doro Shin, Pharma Intelligence's Thought Leadership Manager.

"Last year's admirable winners included Kite Pharma for its groundbreaking CAR-T therapy, and IBM Watson Health, Novartis & Highlands Oncology for their collaborative, and transformative, technological development. The event was a huge success and we're looking forward to replicating this in April," states Karen Currie, Executive Director of Trialtrove, Sitetrove, and Pharmaprojects.

The third annual CARE Awards will once again honor the achievements of the dedicated individuals, teams and organizations committed to advancing human health through clinical research, despite the day-to-day challenges. The eleven categories for the awards have been designed to showcase key accomplishments, including excellence in rare disease drug development, clinical trials conduct and design, technological advancements, and collaborative efforts between teams.

This year's categories are as follows:

  • Most Successful Early Phase Research (Preclinical & Phase I)
  • Excellence in Rare Disease Drug Development
  • Best Patient Centric Clinical Trial
  • Clinical Research Team of the Year
  • Most Innovative Clinical Trial Design
  • Clinical Trial Result of the Year
  • Best Patient-Focused Technological Development
  • Best Sponsor-Focused Technological Development
  • Clinical Partnership of the Year
  • Best in Health Economics & Outcomes Research
  • Lifetime Achievement

"The pharmaceutical industry is driven by an ambition to change the healthcare landscape across the world and improve quality of life. A lot of effort goes into every aspect of the R&D pipeline and the CARE Awards specifically highlight and applaud the commitment and dedication of those individuals, teams and organizations involved," adds Linda Blackerby, President of Pharma Intelligence. "We encourage nominations from across the globe, and look forward to celebrating the achievements of the winners and commending all nominees for their work."

Contact
Karen Currie
Executive Director, Editorial
Contact:  617-639-5594 
Email: Karen.currie@informa.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Informa Business Intelligence via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.

Senaste pressmeddelandena från NASDAQ OMX

Stillfront Group AB: Stillfront one of Sweden's fastest growing companies19.10.2017 11:00Pressmeddelande

PRESS RELEASE   October 19, 2017   Stillfront included in Deloitte Sweden Technology Fast 50  Stillfront has been included in Deloitte Sweden Technology Fast 50. Deloitte Sweden Technology Fast 50 is a ranking of Sweden's 50 fastest growing technology companies, based on revenue growth over the last four years. The ranking includes public and private companies, large and small, in all areas of technology, from internet specialists to biotech, digital media technology to life sciences, computers to semiconductors and software to telecommunications. Please find more detailed information (in Swedish) on www.deloitte.se/fast50. Stillfront has since the IPO in the autumn of 2015 recorded a continuous high and profitable growth in revenues rolling 12 months. Since the IPO, Stillfront has increased the number of so-called core products (i.e. games that have more than 5 MSEK in annual revenue rate) from four to fourteen and the number of studi

Stillfront Group AB: Stillfront ett av Sveriges snabbast växande teknikföretag19.10.2017 11:00Pressmeddelande

PRESSMEDDELANDE   2017-10-19   Stillfront med i Deloitte Sweden Technology Fast 50 Stillfront har kommit med i Deloitte Sweden Technology Fast 50 2017. Deloitte Sweden Technology Fast 50 är en ranking av Sveriges 50 snabbast växande teknologiföretag, baserat på tillväxten i nettoomsättningen de senaste fyra åren. Rankingen inkluderar såväl publika som privata bolag och omfattar all typ av teknologi, från mjuk- och hårdvara till life science, kommunikation och clean technology. Mer information finns på: www.deloitte.se/fast50. Stillfront har sedan noteringen hösten 2015 varje kvartal uppvisat en kontinuerlig hög och lönsam intäktstillväxt rullande 12 månader. Stillfront har sedan noteringen ökat antalet så kallade kärnprodukter (dvs spel som omsätter mer än 5 MSEK i årstakt) från fyra till fjorton och antalet studios har ökat från fyra till åtta. "Stillfront har åtnjutit en enastående tillväxt de senaste åren. Vår tillväxt bygger på vår s

Payvision's annual report reveals cross-border ecommerce trends in 201719.10.2017 09:00Pressmeddelande

With online marketplaces and consumer technology leading the way for growth AMSTERDAM, The Netherlands, Oct. 19, 2017 (GLOBE NEWSWIRE) -- Payvision, global acquirer and data-driven omnichannel solutions provider, has published the findings of its fifth annual cross-border ecommerce research report, in collaboration with Juniper Research. The paper includes the results of a global survey of various industry players regarding the game-changers, the biggest challenges, the best practices for going cross-border, and much more. When compared to last year's findings, the report reveals a new and exciting context for global cross-border trade. The compound annual growth rate predicted for the next three years for cross-border ecommerce is now 17%, whereas it stands at just 12% for ecommerce overall. Also, over the past 12 months, merchants' attitudes towards cross-border ecommerce have become more positive, with 50% of respondents agreeing and 31% strongly

High Seizure Frequency in Children with Dravet Syndrome Negatively Impacts Quality of Life, New International Caregiver Survey Finds19.10.2017 08:00Pressmeddelande

Global survey of 584 caregivers of children, young adults and adults with Dravet illustrates the detrimental effect of debilitating, frequent seizures on quality of life and co-morbidities Results suggest a need for more effective antiepileptic treatments EMERYVILLE, Calif. and BREST, France, Oct. 19, 2017 (GLOBE NEWSWIRE) -- The Dravet Syndrome European Federation and Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, announced today the publication of the initial results from a landmark survey into the clinical, social and economic consequences of Dravet syndrome on children, young adults and their families in Developmental Medicine & Child Neurology [doi:10.1111/dmcn.13591]. This study was led by Lieven Lagae, M.D., Ph.D., Professor at the University of Leuven, Belgium, Head of the Pediatric Neurology Department and Director of the Childhood Epilepsy

XBiotech Announces First Patient in Study Evaluating MABp1 in Combination with Onivyde® and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer18.10.2017 16:53Pressmeddelande

AUSTIN, Texas, Oct. 18, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today enrollment of the first patient into a Phase I single arm study evaluating the maximum tolerated dose of Onivyde® (Irinotecan liposome injection) and 5-fluorouracil/folinic acid in combination with MABp1 in a cohort of patients with advanced pancreatic adenocarcinoma and cachexia. The patient has begun treatment at Cedars-Sinai Medical Center under the care of Dr. Andrew Hendifar, the Study's Principle Investigator, Medical Oncology lead for the Gastrointestinal Disease Research Group and Co-Director of Pancreas Oncology at Cedars-Sinai. A total of 16 patients are expected to be enrolled in the study. Dr. Hendifar commented, "We are excited to enroll our first patient in this novel combinatorial therapy for the treatment of advanced pancreatic cancer and cachexia. This is the first attempt to add an anti-inflammatory therapy to standard chemotherapy in an effort to improve the performanc

Nasdaq and SGX Establish Collaborative Listings Agreement18.10.2017 15:42Pressmeddelande

NEW YORK and SINGAPORE, Oct. 18, 2017 (GLOBE NEWSWIRE) -- Nasdaq Inc. (Nasdaq:NDAQ) and Singapore Exchange (SGX) today announced the signing of a collaborative agreement in a move to leverage their strengths as two of the leading listings venues in the U.S. and Asia respectively. The new agreement seeks to enhance the channels available for companies to access capital market funding and enhance their corporate profile in both markets. As part of this agreement, Nasdaq and SGX -- who also share a successful, long-term market technology relationship -- are currently exploring the demand among corporates for a concurrent or sequential listing on both exchanges. Nasdaq and SGX are committed to supporting companies that are interested in pursuing this route. "The business landscape today is borderless," said Loh Boon Chye, CEO, SGX. "Fast-growing Asian companies looking to tap the capital markets can choose to list on SGX on Asian home ground, and embark on a listing on Nasdaq

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum